Keywords: glaxosmithkline, axe, staff, uk-headquartered, world, second, largest
GlaxoSmithKline to axe 850 R&D staff
Article | 06 October 2008
UK-headquartered GlaxoSmithKline, the world's second largest drugmaker by sales, has announced plans to dramatically reduce its R&D head count, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
